Argus
•
Aug 19, 2026
VCEL: Lowering target price to $46.00
Summary
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets.
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
PTCT: Lowering target price to $67.00
Sep 02, 2026
•
PTCT
KRYS: Raising target price to $400.00
Sep 02, 2026
•
KRYS
PTGX: Lowering target price to $154.00
Sep 02, 2026
•
PTGX
BLFS: Lowering target price to $37.00
Sep 02, 2026
•
BLFS
VCYT: What does Argus have to say about VCYT?
Sep 02, 2026
•
VCYT
